Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Mertens

Showing results (171-180 of 211) with videos related to

Pageof 22
Sort By:
BJU International|February 19, 2025
Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancerPietro Scilipoti, Mattia Longoni, Mario de Angelis, et al.
European Urology|July 20, 2020
FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?<sup>†</sup>Bas W G van Rhijn, Laura S Mertens, Roman Mayr, et al.
Urologic Oncology|April 4, 2026
Risk stratification of Ta high-grade non-muscle-invasive bladder cancer: Insights from a multicenter cohort studyPaolo Zaurito, Pietro Scilipoti, Mattia Longoni, et al.
Urologic Oncology|April 12, 2026
The impact of age in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-GuérinPietro Scilipoti, Paolo Zaurito, Mattia Longoni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 20, 2016
Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatmentD Pouessel, Y Neuzillet, L S Mertens, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|October 18, 2023
The effect of cisplatin-based neoadjuvant chemotherapy on the renal function of patients undergoing radical cystectomyMatthew D Ho, Anna J Black, Homayoun Zargar, et al.
Urologic Oncology|December 15, 2021
Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patientsLaura S Mertens, Francesco Claps, Roman Mayr, et al.
Cancers|February 25, 2022
Compared Efficacy of Adjuvant Intravesical BCG-TICE vs. BCG-RIVM for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): A Propensity Score Matched AnalysisFrancesco Del Giudice, Rocco Simone Flammia, Benjamin I Chung, et al.
European Urology Focus|August 11, 2020
Nomogram Predicting Bladder Cancer-specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International ConsortiumMaria Carmen Mir, Michele Marchioni, Homi Zargar, et al.
European Urology Oncology|February 14, 2024
Unlocking the Potential of Adequate Bacillus Calmette-Guérin Immunotherapy in Very-high-risk Non-muscle-invasive Bladder Carcinoma: A Multicenter Analysis of Oncological Outcomes and Risk DynamicsJosé Daniel Subiela, Wojciech Krajewski, Daniel A González-Padilla, et al.
Pageof 22

Showing results (171-180 of 211) with videos related to

Sort By:
Pageof 22
BJU International|February 19, 2025
Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancerPietro Scilipoti, Mattia Longoni, Mario de Angelis, et al.
European Urology|July 20, 2020
FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?<sup>†</sup>Bas W G van Rhijn, Laura S Mertens, Roman Mayr, et al.
Urologic Oncology|April 4, 2026
Risk stratification of Ta high-grade non-muscle-invasive bladder cancer: Insights from a multicenter cohort studyPaolo Zaurito, Pietro Scilipoti, Mattia Longoni, et al.
Urologic Oncology|April 12, 2026
The impact of age in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-GuérinPietro Scilipoti, Paolo Zaurito, Mattia Longoni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 20, 2016
Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatmentD Pouessel, Y Neuzillet, L S Mertens, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|October 18, 2023
The effect of cisplatin-based neoadjuvant chemotherapy on the renal function of patients undergoing radical cystectomyMatthew D Ho, Anna J Black, Homayoun Zargar, et al.
Urologic Oncology|December 15, 2021
Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patientsLaura S Mertens, Francesco Claps, Roman Mayr, et al.
Cancers|February 25, 2022
Compared Efficacy of Adjuvant Intravesical BCG-TICE vs. BCG-RIVM for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): A Propensity Score Matched AnalysisFrancesco Del Giudice, Rocco Simone Flammia, Benjamin I Chung, et al.
European Urology Focus|August 11, 2020
Nomogram Predicting Bladder Cancer-specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International ConsortiumMaria Carmen Mir, Michele Marchioni, Homi Zargar, et al.
European Urology Oncology|February 14, 2024
Unlocking the Potential of Adequate Bacillus Calmette-Guérin Immunotherapy in Very-high-risk Non-muscle-invasive Bladder Carcinoma: A Multicenter Analysis of Oncological Outcomes and Risk DynamicsJosé Daniel Subiela, Wojciech Krajewski, Daniel A González-Padilla, et al.
Pageof 22